GMED or MASI: Which Is the Better Value Stock Right Now?

Core Viewpoint - Investors in the Medical - Instruments sector may find value in either Globus Medical (GMED) or Masimo (MASI), with a closer examination needed to determine which stock is more appealing to value investors [1] Valuation Metrics - Both GMED and MASI currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - The Value category assesses undervalued companies using key metrics such as P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] - GMED has a forward P/E ratio of 22.92 and a PEG ratio of 1.45, while MASI has a forward P/E of 30.36 and a PEG ratio of 1.77 [5] - GMED's P/B ratio is 2.77, contrasting with MASI's P/B of 11.61, indicating GMED is more favorably valued [6] - Based on these valuation metrics, GMED is rated with a Value grade of B, while MASI has a Value grade of D, suggesting GMED is the superior value option [6]